This summer in 2026, the Food and Drug Administration (FDA) approved the marketing of a new medication for the management of attention deficit disorder with or without hyperactivity (ADHD): centanafadine, sold under the brand name Simtriyo. The drug is described as a leader in a new therapeutic class, but experts suggest it may not be a major breakthrough in the treatment of ADHD. The medication is approved for use in both adults and children aged six and older who live with this neurodevelopmental condition. ADHD is a common disorder that affects a person's ability to focus, control impulses, and manage hyperactivity. It is often treated with stimulant medications, but these can sometimes cause side effects or lead to dependency. The introduction of Simtriyo adds another option to the existing treatments, offering healthcare providers and patients more choices in managing symptoms. Centanafadine is classified as a psychotropic drug, meaning it affects the mind or mental state. It works by altering the levels of certain neurotransmitters in the brain, which are chemicals that help transmit signals between nerve cells. While the drug is described as part of a new class of treatments, its mechanism of action is somewhat similar to existing medications, which has led some experts to question whether it represents a significant advancement in ADHD care. The approval of Simtriyo highlights the ongoing efforts to improve ADHD treatment options. As more research is conducted, healthcare professionals will continue to evaluate how effective and safe this new medication is compared to existing therapies. Patients and doctors will likely monitor its performance in real-world settings to determine its place in the broader treatment landscape.